Article
Impact of JAK2(V617F) mutation status on treatment response to anagrelide in essential thrombocythemia: an observational, hypothesis-generating study.
Drug design, development and therapy - 1 Jan 2015
Cascavilla Nicola, De Stefano Valerio, Pane Fabrizio, Pancrazzi Alessandro, Iurlo Alessandra, Gobbi Marco, Palandri Francesca, Specchia Giorgina, Liberati A Marina, D'Adda Mariella, Gaidano Gianluca, Fjerza Rajmonda, Achenbach Heinrich, Smith Jonathan, Wilde Paul, Vannucchi Alessandro M
Abstract excerpt
A JAK2(V617F) mutation is found in approximately 55% of patients with essential thrombocythemia (ET), and represents a key World Health Organization diagnostic criterion. This hypothesis-generating study (NCT01352585) explored the impact of JAK2(V617F) mutation status on treatment response to anagrelide in patients with ET who were intolerant/refractory to their current cytoreductive therapy. The primary...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
